n (%)†
*Differences between means within each variable differed significantly p<0·005 (t-test for independent samples for sex, illicit drug use and psychological distress); ANOVA for age groups, occupational status, psychoactive medicinal drug use and alcohol use patterns).
†Differences between categories within each variable except for sex differed significantly p<0.005 (chi-squared (χ²) test for 2×n tables).
ANOVA, one-way analysis of variance; AUDIT-4, Alcohol Use Disorder Identification Test 4; SCL-5, Symptom Checklist 5.
The number of disorders and the proportion of patients with multimorbidity increased significantly with age and was higher for those being non-economically active and retired. Men had a significantly higher number of disorders compared with women ( table 1 ). Of the young patients (18–34 years) 35.0% were multimorbid ( table 1 ). Of these, 40.3% used alcohol above the recommended guidelines, 12.6% used it hazardously and 8.9% in a risky manner. Prevalence of risky alcohol use was higher among patients aged 35–49 years and 50–64 years (12.7% and 12.1%) and decreased slightly for those aged 65–79 years (8.7%). Of the young multimorbid patients (18–34 years) 14.1% used illicit drugs, 14.1% used psychoactive medicinal drugs and 31.4% reported to have psychological distress. Compared with the young patients, 18–34 among multimorbid patients aged ≥35 the prevalence of psychological distress decreased with increasing age (for those aged 35–49 years the prevalence was 30.2%; for those 50–64 years it was 26.3%; 65–79 years: 23.9% and for those >80 years it was 13.8%) while the prevalence of psychoactive medicinal drug use increased substantially with increasing age (for those aged 35–49 years the prevalence was 32.6%; for those 50–64 years it was 45.4%; 65–79 years: 43.8% and for those >80 years it was 41.2%). Illicit drugs were most prevalent among those aged 35–64 years (16.9%) and decreased substantially with increasing age (for those 50–64 years it was 10.7%; 65–79 years 1.3% and for those >80 years it was 0.8%).
The prevalence of multimorbidity in patients using psychoactive medicinal drugs was higher (68.7%, mean number of disorders: 2.56; SD: 1.61) than for those using illicit drugs (62.0%, mean number of disorders: 2.23; SD: 1.47) ( table 1 ). 65.5% of those using one medication and 73.3% using ≥2 medications were multimorbid, respectively ( table 1 ).
Overall, 85.5% of patients with multimorbidity used any of the three substance groups, either individually or in combination with each other. The prevalence of individual and combined substance use is shown in table 2 . Of all patients, 2.9% used all three substance groups concomitantly, and of these 61.8% were multimorbid compared with those without multimorbidity (38.2%). The most frequent combination of substances was alcohol and psychoactive medicinal drugs (18.3%). Of a total of 787 patients using psychoactive medicinal drugs ( table 1 ), only 28.2% used these alone and not in combination with illicit drugs or alcohol. Combinations of drugs in general were more prevalent in patients with multimorbidity compared with those without multimorbidity, except for the combination of illicit drugs and alcohol, which was more frequent among those without multimorbidity (53.5% vs 46.5%) (table 2).
Prevalence of individual substance use and combined substance use (alcohol use includes any level of drinking, from low-risk drinking to risky drinking) among patients with and without multimorbidity (single diseased)
N (%) | Single-diseased patients n (%)* | Patients with multimorbidity n (%)* |
All patients (n=2359, 100%) | 1018 (43.2) | 1341 (56.8) |
Not taken any drug (n=308, 13.1%) | 114 (37.0) | 194 (63.0) |
Combined substance use | ||
Combined illicit drugs and alcohol (n=43, 1.8%) | 23 (53.5) | 20 (46.5) |
Combined psychoactive medicines and alcohol (n=432, 18.3%) | 154 (35.6) | 278 (64.4) |
Combined psychoactive medicines and illicit drugs (n=24, 1.0%) | 7 (29.2) | 17 (70.8) |
Combined all three substances (n=68, 2.9%) | 26 (38.2) | 42 (61.8) |
Individual substance use | ||
Only psychoactive medicines (n=222, 9.4%) | 45 (20.3) | 177 (79.7) |
Only alcohol (n=1253, 53.1%) | 648 (51.7) | 605 (48.3) |
Only illicit drugs (n=9, 0.4%) | 1 (11.1) | 8 (88.9) |
*Differences between the prevalence of psychoactive substance use and combination of substances among single- diseased and those with multimorbidity differed significantly with a p<0.001 for all of the substances and combinations of substances (chi-squared (χ²) test for 2×n tables).
Table 3 depicts the ORs for the association between multimorbidity and the predictor variables including alcohol use patterns, illicit and psychoactive medicinal drug use, and psychological distress. The likelihood for being multimorbid increased substantially with increasing age. Patients with risky alcohol use were more likely to be multimorbid compared with those with low risk drinking habits (OR 1.53; 95% CI 1.05 to 2.24), the same applied to abstainers (OR 1.50; 95% CI 1.15 to 1.95). Multimorbidity was not significantly associated with hazardous drinking (OR 1.18; 95% CI 0.81 to 1.71). There was a significant positive association between multimorbidity and psychoactive medicinal drug use (OR 1.34; 95% CI 1.07 to 1.67), and multimorbidity and psychological distress (OR 1.28 95% CI 1.01 to 1.63). No significant association between multimorbidity and illicit drugs was detected.
ORs for multimorbidity by age, sex, occupational status, psychological distress and substance use (n=2136)
Multimorbidity (unadjusted OR, 95% CI) | Multimorbidity (adjusted OR, 95% CI)* | |
Male (vs female) | 0.87 (0.74 to 1.01) | 0.95 (0.78 to 1.16) |
Age years | ||
18–34 | Reference | Reference |
35–549 | 1.51 (1.17 to 1.95) | 1,24 (0.92 to 1.66) |
50–64 | 2.50 (1.98 to 3.17) | 1.98 (1.48 to 2.64) |
65–79 | 4.23 (3.35 to 5.34) | 3.18 (2.06 to 4.93) |
≥80 | 8.66 (6.22 to 12.07) | 6.72 (3.79 to 11.90) |
Occupational status | ||
Economically active | Reference | Reference |
Retired | 4.23 (3.52 to 5.07) | 1.36 (0.91 to 2.03) |
Economically non-active | 2.85 (2.24 to 3.62) | 1.50 (1.10 to 2.05) |
Psychological distress (SCL-5) | 1.43 (1.18 to 1.74) | 1.28 (1.01 to 1.63) |
Substance use | ||
Alcohol use patterns | ||
Low-risk drinking (scores 1–3) | Reference | Reference |
Abstinence (score 0) | 1.79 (1.44 to 2.22) | 1.50 (1.15 to 1.95) |
Alcohol use in excess of low-risk guidelines (scores 4–6) | 0.71 (0.59 to 0.87) | 0.96 (0.76 to 1.21) |
Hazardous drinking (scores 7–8) | 0.74 (0.54 to 1.02) | 1.18 (0.81 to 1.71) |
Risky alcohol use and possible alcohol dependence (scores ≥9) | 1.41 (1.02 to 1.94) | 1.53 (1.05 to 2.24) |
Psychoactive medicinal drugs | 2.09 (1.75 to 2.50) | 1.34 (1.07 to 1.67) |
Illicit drugs | 1.26 (0.90 to 1.76) | 1.22 (0.80 to 1.85) |
*All adjusted for the other listed variables in model.
SCL-5, Symptom Checklist 5.
The results from our sensitivity analyses were similar to those from the main regression model ( online supplemental table 1 ) except for self-reported psychological distress which was not significantly associated with multimorbidity. The ORs for all variables included in the model were slightly attenuated and remained significantly associated with multimorbidity.
In this study of acute medically ill patients, we found an association between multimorbidity and psychological distress, psychoactive medicinal drug and risky alcohol use. No association between multimorbidity and illicit drug use was found. Substance use was widespread and the majority of multimorbid patients used alcohol and psychoactive medicinal drugs and a combination of both.
Our findings are commensurate with prior reports on the high prevalence of multimorbidity among those non-economically active and older populations and the association between ageing and multimorbidity. 1 34 The increase in global ageing and long-term conditions indicate that the number of people with multimorbidity in the future is set to rise. 1 Older adults are often not screened for SUDs. 9 This underpins the importance of the identification of substance use among the elderly; which if not integrated in the disease management might compromise their treatment effectiveness. This applies particularly to alcohol which was widely used by the older patients in our study, which are prescribed medications for multiple conditions. Therefore, the probability for adverse events, non-adherence and drug interactions might be elevated due to the diminished metabolic efficiency for both alcohol and other substances and requires careful management among the older patients drinking in a risky manner. 35 36 Nevertheless, in our study, the prevalence of multimorbidity among the young patients (18-34) was high (35%). The reason for this might be that our hospital comprises patients from boroughs with low income and low life expectation rates in Norway. 25 This finding is in concordance with other studies reporting an earlier manifestation of multimorbidity among those socioeconomically deprived. 34 The majority of the young patients in our study used substances, and one-third reported to have psychological distress. From a preventive perspective, the young patients should be timely targeted in view of their substance use, mental health and overall morbidity in order to avoid decrements in quality of life, health complications and possible frailty in later stages of life.
Patients with psychological distress were more likely to be multimorbid compared with single-diseased patients. However, our sensitivity analysis showed that this association did not remain after removal of mental- and behavioural disorders. This might indicate that self-reported psychological distress was mainly associated to mental and behavioural disorders, as previously reported. 6
The observed augmented risk for multimorbidity among abstainers in our main analysis may reflect the fact that some former drinkers became abstainers due to health problems. 37 These results indicate that risky alcohol use should be considered in a multifaceted management regimen for multimorbid patients.
The prevalence of psychoactive medicinal drug use was higher among multimorbid patients compared with single-diseased patients. Nonetheless, 73.3% of patients using two or more psychoactive medical drugs were multimorbid, which might reflect a plausible unhealthy drug use. Clinical guidelines rarely account for multimorbidity. 38 As a result, patients with multimorbidity might be prescribed several drugs, although each of these is recommended by a disorder-specific guideline, leading to a possibly higher number of drugs used. However, we examined only psychoactive medicinal drugs, and some of the patients might have used them non-medically. Regardless of the manner of use, when several psychoactive medications are used by multimorbid patients the risk of drug–drug interactions increases with the number of co-existing disorders and the number of drugs taken. 39
More than half of the patients combining all three substances were multimorbid. The adverse effects of multimorbidity and substance use on the functioning and quality of life might be greater than the individual effects expected from multimorbidity or substance use alone. A high proportion of multimorbid patients combined psychoactive medicinal drugs and alcohol. Patients used mainly benzodiazepines, opioids and z-hypnotics; which when combined with alcohol might generate an additive effect with increased CNS suppression and an increased risk of adverse events and fatal outcomes, even when the individual substances are used as prescribed. 40 Regarding this, assessing alcohol use among multimorbid patients using prescription psychoactive medications should be a priority, in order to target patients that need to reduce their alcohol use. Furthermore, interventions that target reductions in alcohol consumption do not necessarily incorporate other substances, except for tobacco use. 41 Given the high prevalence of substance use among hospitalised populations, including ours, other substances should be incorporated alongside alcohol interventions. 11
Only a minority of patients did use illicit drugs alone, these were mostly combined with alcohol and psychoactive medicinal drugs. Since patients are more prone to using psychoactive medicinal drugs non-medically, the combination of illicit and psychoactive medicinal drugs might indicate a non-medical use of these prescription drugs. 42 A combination of psychoactive medicinal and illicit drugs can have serious medical consequences, reflected in increased ED visits. 11 43 Furthermore, use of illicit drugs may impair adherence to prescribed controlled regimens in some patients and cause detrimental drug-drug interactions. 44 Given the under-reporting in both psychoactive medicinal and illicit drugs, 31 45 blood sample screening might be an appropriate tool to assess drug use and deliver adequate care to these patients.
More than half of our patient population was multimorbid. Patients with multimorbidity have more frequent and complex interactions with the healthcare services and account for substantial healthcare costs. 46 Integrating substance use in the disease management of patients with multimorbidity is important for the burden reduction on the healthcare system. Several brief instruments measuring substance use in addition to blood sample screening may be used and should be a priority among patients with multimorbidity. 47 48 Furthermore, monitoring multimorbidity in relation to substance use might mitigate this significant public health challenge. In view of its magnitude, an improvement will require a coherent and focused action across multiple sectors and among policy-makers.
Due to the cross-sectional design of the study, the ability to make casual inference was limited. However, this was beyond the scope of this study.
The use of blood samples for assessment of psychoactive medicinal and illicit drugs does not compare directly to self-reported alcohol use which measures alcohol consumption during a year period. Nonetheless, an under-reporting of drug use is evident in studies comparing self-reported drug use with biological samples. 31 45 49 Therefore, a recent and objective blood sample might reflect to an extent the drug use among patients. Given the dose–response association between AUDIT-4 and the biological marker phosphatidylethanol, 24 the results from all three substance groups are to a great extent comparable to each other.
We were not able to distinguish between medical and non-medical use of psychoactive prescription drugs. Regardless of manner of use, examining their distribution, concomitant use and combination patterns with other substances in patients with multimorbidity is of importance.
Finally, the inclusion of acute diseases and other signs and symptoms might have inflated the prevalence of multimorbidity. 50 However, this might reflect a more realistic daily clinical practice, as previously suggested. 51
The observed association between multimorbidity and risky alcohol use, and psychoactive medicinal drug use among patients adds further value to the evidence on substances’ harms to health.
Our findings call for more research on multiple psychoactive substance use and multimorbidity. Research on the relationship between multimorbidity and substance use patterns and/or drug–drug interactions among medical patients at all ages is warranted. Consequently, this may have great implications for the clinical practice and public health.
Twitter: @AnnersLerdal
Contributors: SK drafted the manuscript and conducted the statistical data analyses. SK, VV, DG, BJ, AL and STB organised or contributed to the data acquisition. SK, TB and BJ organised and conducted the laboratory analyses. TAH and all authors were responsible for study design, interpretation of findings, critical revision of the article and final approval of the manuscript. STB is the guarantor of this study.
Funding: The study was partly sponsored by the Ministry of Health and Care Services, Oslo, Norway (Grant B-1408).
Disclaimer: The sponsor had no role in the study design, in the collection, analyses or interpretation of the data, in the writing of the report or the decision to submit for publication.
Competing interests: None declared.
Provenance and peer review: Not commissioned; externally peer reviewed.
Supplemental material: This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.
Ethics statements, patient consent for publication.
Not applicable.
The study was approved by Regional Ethics Committee for South Eastern Norway (2015/2404).
IMAGES
VIDEO
COMMENTS
A cross-sectional study is a type of research design in which you collect data from many different individuals at a single point in time. In cross-sectional research, you observe variables without influencing them. Researchers in economics, psychology, medicine, epidemiology, and the other social sciences all make use of cross-sectional studies ...
A cross-sectional study is a type of research design in which you collect data from many different individuals at a single point in time. In cross-sectional research, you observe variables without influencing them. Researchers in economics, psychology, medicine, epidemiology, and the other social sciences all make use of cross-sectional studies ...
Cross-Sectional vs. Longitudinal. A cross-sectional study design is a type of observational study, or descriptive research, that involves analyzing information about a population at a specific point in time. This design measures the prevalence of an outcome of interest in a defined population. It provides a snapshot of the characteristics of ...
Cross-Sectional Design: Descriptive. Cross-sectional studies can be descriptive and analytic (Alexander, 2015a).Descriptive cross-sectional studies characterize the prevalence of health outcomes or phenomena under investigation.Prevalence is measured either at a one-time point (point prevalence), over a specified period (period prevalence) (Alexander, 2015a), or as a cross-sectional serial ...
Introduction. Cross-sectional study design is a type of observational study design. As discussed in the earlier articles, we have highlighted that in an observational study, the investigator does not alter the exposure status. The investigator measures the outcome and the exposure (s) in the population, and may study their association.
A cross-sectional study is a type of observational research design that analyzes data from a population, or a representative subset, at one specific point in time. Unlike longitudinal studies that observe the same subjects over a period of time to detect changes, cross-sectional studies focus on finding relationships and prevalences within a ...
A cross-sectional study, or cross-sectional analysis, is a type of observational research design that involves the collection of data from a sample of individuals or subjects at a single point in time. Read this article to for more details on what a cross sectional study is, limitations, advantages, disadvantages, and examples.
A cross-sectional study is an experimental design that analyzes data from a representative sample at a specific point in time. Researchers usually evaluate multiple attributes at once when using this design. Unlike longitudinal studies, these studies don't track changes over time. These studies are a snapshot of a moment in time.
As is the case for most study types a larger sample size gives greater power and is more ideal for a strong study design. Within a cross-sectional study a sample size of at least 60 participants is recommended, although this will depend on suitability to the research question and the variables being measured. A suitable number of variables.
The term cross-sectional research design is typically used in opposition to longitudinal research designs. It may thus be defined as a design without repeated measurements of the same attribute of any individual unit i = 1, … , N (e.g., a person). Although no repeated measures are taken for the same unit of interest, cross-sectional designs are often used for longitudinal inferences, for ...
A cross-sectional study is a type of observational research that analyzes data of variables collected at one given point in time across a sample population or a pre-defined subset. This study type is also known as cross-sectional analysis, transverse study, or prevalence study. Although this research does not involve conducting experiments ...
Abstract. Cross-sectional studies are observational studies that analyze data from a population at a single point in time. They are often used to measure the prevalence of health outcomes, understand determinants of health, and describe features of a population. Unlike other types of observational studies, cross-sectional studies do not follow ...
The cross-sectional design can only measure differences between or from among a variety of people, subjects, or phenomena rather than a process of change. As such, researchers using this design can only employ a relatively passive approach to making causal inferences based on findings. ... This type of research design draws a conclusion by ...
Cross-sectional studies allow researchers to look at numerous characteristics at once (age, income, gender, etc.) Since cross-sectional research data is gathered all at once, multiple variables can be assessed simultaneously. This is especially useful if you're interested in exploring associations between sets of variables.
The bottom line. A cross-sectional study is essential when researching the prevailing characteristics in a given population at a single point in time. Cross-sectional studies are often used to analyze demography, financial reports, and election polls. You could also use them in medical research or when building a marketing strategy, for instance.
Cross-sectional studies are a type of observational studies in which the researcher commonly assesses the exposure, outcome, and other variables (such as confounding variables) at the same time. They are also referred to as " prevalence studies. " These studies are useful in a range of disciplines across the social and behavioral sciences.
A cross-sectional study (also known as a cross-sectional analysis, transverse study, prevalence study) is a type of observational study that analyzes data from a population, or a representative subset, at a specific point in time. It examines the relationship between diseases (or other health-related states) and other variables of interest as ...
In medical research, a cross-sectional study is a type of observational study design that involves looking at data from a population at one specific point in time. In a cross-sectional study, investigators measure outcomes and exposures of the study subjects at the same time. It is described as taking a "snapshot.
An analytical cross-sectional study is a type of quantitative, non-experimental research design. These studies seek to "gather data from a group of subjects at only one point in time" (Schmidt & Brown, 2019, p. 206). The purpose is to measure the association between an exposure and a disease, condition or outcome within a defined population.
Step 1: Consider your aims and approach. Step 2: Choose a type of research design. Step 3: Identify your population and sampling method. Step 4: Choose your data collection methods. Step 5: Plan your data collection procedures. Step 6: Decide on your data analysis strategies. Other interesting articles.
Longitudinal studies and cross-sectional studies are two different types of research design. In a cross-sectional study you collect data from a population at a specific point in time; in a longitudinal study you repeatedly collect data from the same sample over an extended period of time. Longitudinal study.
16. Cross-Sequential Design. Combines elements of cross-sectional and longitudinal research to examine both age-related changes and cohort differences. The selection of a specific research design method should align with the research objectives, the type of data needed, available resources, ethical considerations, and the overall research approach.
3. The possibility of research bias in a cross-sectional study: There can be an issue in a cross-sectional study if the characteristics of the participants are different from the characteristics of the nonparticipants. This can lead to bias in the outcome of the study. Read: Experimental Research Designs: Types, Examples & Methods
Purkey's cross-sectional studies, however, only from longitudinal research, which points to the limitations of cross-sectional studies. As an example of a repeated cross-sectional design, consider the High School and Beyond (HS&B) Study [1] that began in 1980 and sampled 1647 high-school students from all regions of the United States.
Study design III: Cross-sectional studies Kate Ann Levin Dental Health Services Research Unit, University of Dundee, Dundee, Scotland, UK In this series, I previously gave an overview of the main types of study design and the techniques used to minimise biased results. Here, I describe cross-sectional studies, their uses, advantages and ...
This study uses data from a cross-sectional observational study conducted from November 2016 to December 2017, and the study design of the data gathering has been previously described in detail. 24 In brief, the study site was Lovisenberg Diaconal Hospital in Oslo, where all patients having acute medical disorders from the defined hospital ...